Molecular-based and alternative therapies for pancreatic cancer: Looking "out of the box"

Cancer Journal (United States)

Volumn 18, Issue 6, 2012, Pages 665-673

  Tholey, Renee ^a   Sawicki, Janet A ^b,c   Brody, Jonathan R ^a,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

molecular based therapy; novel therapeutic options; Pancreatic ductal adenocarcinoma (PDA)

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 8542; DIPHTHERIA VACCINE; FLUOROURACIL; FOLINIC ACID; GELATINASE A; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; MARIMASTAT; MATRIX METALLOPROTEINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PACLITAXEL; SARIDEGIB; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER NANOTHERAPY; CANCER PATIENT; CELL POPULATION; DNA DAMAGE; DNA REPAIR; DRUG INDUSTRY; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MOLECULAR GENETICS; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; TUMOR MICROENVIRONMENT; UNITED STATES;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; COMPLEMENTARY THERAPIES; HUMANS; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84871253900     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182793ff6     Document Type: Review

References (85)

1. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, NY). 2008;321:1801-1806.
2. Lowery MA, Kelsen DP, Stadler ZK, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011;16:1397-1402.
3. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (New York, NY). 2009;324:1457-1461.
4. Shen K, Rice SD, Gingrich DA, et al. Distinct genes related to drug response identified in ER positive and ER negative breast cancer cell lines. PloS One. 2012;7:e40900.
5. Young A, Lyons J, Miller AL, et al. Ras signaling and therapies. Adv Cancer Res 2009;102:1-17.
6. Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvi-ronment. Clin Cancer Res. 2012;18:4266-4276.
7. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (New York, NY). 2002;295:2387-2392.
8. Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001;19:3447-3455.
9. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002;87:161-167.
10. Zhao M, Tominaga Y, Ohuchida K, et al. Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer. Cancer Sci. 2012;103:58-66.
11. Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metallo-proteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009;69:1517-1526.
12. Chu GC, Kimmelman AC, Hezel AF, et al. Stromal biology of pancreatic cancer. J Cell Biochem. 2007;101:887-907.
13. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007;6:1186-1197.
14. Wehr AY, Furth EE, Sangar V, et al. Analysis of the human pancreatic stellate cell secreted proteome. Pancreas. 40:557-566.
15. Erkan M, Adler G, Apte MV, et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut. 2012;61:172-178.
16. Vonlaufen A, Joshi S, Qu C, et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 2008;68:2085-2093.
17. Spector I, Honig H, Kawada N, et al. Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development. Pancreas. 2010;39:1008-1015.
18. Hwang RF, Moore TT, Mertens Hattersley M, et al. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer. Mol Cancer Res.
19. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-4554.
20. Tsujie M, Nakamori S, Nakahira S, et al. Human equilibrative nucleo-side transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007;27:2241-2249.
21. Marechal R, Bachet JB, Mackey JR, et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology. 2012;143:664-74 e6.
22. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25:319-325.
23. Le A, Rajeshkumar NV, Maitra A, et al. Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res. 2012;18:4285-4290.
24. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med. 2004;350:1461-1463.
25. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J (Sudbury, Mass). 2010;16:336-341.
26. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253:328-335.
27. Chung HW, Jang S, Lim JB. Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class I chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma. Cancer. 2012; Epub ahead of print.
28. Roy LD, Sahraei M, Subramani DB, et al. MUC1 enhances invasive-ness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 2011;30:1449-1459.
29. Chen J, Li HY, Wang D, et al. Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro. J Gastroenterol Hepatol. 26: 1509-1518.
30. Schettini J, Kidiyoor A, Besmer DM, et al. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunol Immunother. 2012; Epub ahead of print.
31. Winter JM, Tang LH, Klimstra DS, et al. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as bio-markers. PLoS One. 2012;7:e40157.
32. Liu L, Meng J, Zhang C, et al. Effects on apoptosis and cell cycle arrest contribute to the antitumor responses of interleukin-27 mediated by retrovirus in human pancreatic carcinoma cells. Oncol Rep. 27:1497-1503.
33. Pan X, Sheng W, Zhu Q, et al. Inhibition of pancreatic carcinoma growth by adenovirus-mediated human interleukin-24 expression in animal model. Cancer Biother Radiopharm. 2008;23:425-434.
34. Witkiewicz A, Williams TK, Cozzitorto J, et al. Expression of indole-amine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg. 2008;206:849-854; discussion 54-56.
35. Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res. 2005;65:8065-8068.
36. Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indole-amine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007;396:203-213.
37. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008;222: 206-221.
38. Scott GN, DuHadaway J, Pigott E, et al. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol. 2009;182:7509-7517.
39. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (New York, NY). 1998;281: 1191-1193.
40. Metz R, Duhadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indole-amine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67:7082-7087.
41. Witkiewicz AK, Costantino CL, Metz R, et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg. 2009;208:781-787; discussion 7-9.
42. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed. 2005;7:60.
43. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol. 2009; 27:433-438.
44. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95:214-221.
45. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913-917.
46. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434: 917-921.
47. Hirai T, Shirai H, Fujimori H, et al. Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation. Cancer Sci. 2012;103:1045-1050.
48. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) poly-merase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361:123-134.
49. Langelier MF, Planck JL, Roy S, et al. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science (New York, NY). 2012;336:728-732.
50. Wiltshire TD, Lovejoy CA, Wang T, et al. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific pep-tidase 11 (USP11) as a regulator of DNA double-strand break repair. J Biol Chem. 2010;285:14565-14571.
51. FDA. Mitoxantrone. Available at: http://www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName= MITOXANTRONE%20HYDROCHLORIDE. Accessed on November 9, 2012.
52. Yang F, Jin C, Subedi S, et al. Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Cancer Treat Rev. 2012; 38:566-579.
53. Showalter SL, Huang YH, Witkiewicz A, et al. Nanoparticulate delivery of diphtheria toxin DNA effectively kills mesothelin expressing pancreatic cancer cells. Cancer Biol Ther. 2008;7:1584-1590.
54. Patra CR, Bhattacharya R, Wang E, et al. Targeted deliveryof gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008;68:1970-1978.
55. Gold DV, Karanjawala Z, Modrak DE, et al. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res. 2007; 13:7380-7387.
56. Glazer ES, Zhu C, Massey KL, et al. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin Cancer Res. 2010;16:5712-5721.
57. Huang YH, Bao Y, Peng W, et al. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc Natl Acad Sci USA. 2009;106:3426-3430.
58. Costantino CL, Witkiewicz AK, Kuwano Y, et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine ki-nase. Cancer Res. 2009;69:4567-4572.
59. Richards NG, Rittenhouse DW, Freydin B, et al. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann Surg. 2010;252:499-505; discussion 6.
60. th Annual Meeting of the American Pancreas Club. May 6-7, 2011. Northwestern University, Chicago, Illinois.
61. th Annual Meeting of the American Pancreas Club. May 6-7, 2011. Northwestern University, Chicago, Illinois.
62. Pineda DM, Rittenhouse DW, Valley CC, et al. HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells. Cancer Biol Ther. 2012;13:946-955.
63. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901-1908.
64. Torrisani J, Bournet B, du Rieu MC, et al. let-7 MicroRNA transfer in pancreatic cancerYderived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Human Gene Ther. 2009;20:831-844.
65. Li Y, VandenBoom TG 2nd, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69:6704-6712.
66. Park JK, Lee EJ, Esau C, et al. Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 2009;38:e190-9.
67. Kluiver J, Gibcus JH, Hettinga C, et al. Rapid generation of microRNA sponges for microRNA inhibition. PloS One. 2012;7:e29275.
68. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PloS One. 2009;4:e6816.
69. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-323.
70. Singh BN, Fu J, Srivastava RK, et al. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PloS One. 2011;6:e27306.
71. Kern SE, Shibata D. The fuzzy math of solid tumor stem cells: a perspective. Cancer Res. 2007;67:8985-8988.
72. Penchev VR, Rasheed ZA, Maitra A, et al. Heterogeneity and targeting of pancreatic cancer stem cells. Clin Cancer Res. 2012;18:4277-4284.
73. New Cancer Research Angle from a Surprising Source. Jefferson Surgical Solutions; 2009;4.
74. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64: 3288-3295.
75. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100Aversus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192-2202.
76. Khokhlova TD, Hwang JH. HIFU for palliative treatment of pancreatic cancer. J Gastrointest Oncol. 2011;2:175-184.
77. Zhao H, Yang G, Wang D, et al. Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer. Anticancer Drugs. 2010;21:447-452.
78. Orsi F, Zhang L, Arnone P, et al. High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations. AJR. 2010;195:W245-252.
79. Cui Y, Brosnan JA, Blackford AL, et al. Genetically defined subsets of human pancreatic cancer demonstrate unique in vitro chemosensitivity. Clin Cancer Res. 2012; Epub ahead of print.
80. Hidalgo M, Von Hoff DD. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res. 2012;18: 4249-4256.
81. Brody JR, Witkiewicz AK, Yeo CJ, et al. The 'RNA-binding ome': future implications for chemotherapeutic efficacy. Future oncology (London, England). 2009;5:1317-1319.
82. Brody JR, Gonye GE. HuR's role in gemcitabine efficacy: an exception or opportunity? WIREs RNA. 2011;2:435-444.
83. Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL, et al. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res. 2012; 18:4257-4265.
84. Brody JR, Gallmeier E, Yoshimura K, et al. A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymi-dylate synthase ternary complexes. Cancer Biol Ther. 2006;5:923-927.
85. Patel K, Yerram SR, Azad NA, et al. A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluor-opyrimidines dosing. Oncotarget. 2012;3:678-685.